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portant to ensure that policy implementation did not
compromise patient outcomes. 
OBJECTIVES: The goals of this study were: 1) to assess
the net economic impact of PA for NSAIDs on WVM ex-
penditures, and 2) to determine the impact of the policy
on patients’ health-related quality of life (HRQoL). 
METHODS: The study was conducted in two phases. In
phase I, a quasi-experimental design was used to analyze
retrospective utilization data of recipients with continuous
Medicaid eligibility over the period of 18 months prior to
and 18 months after implementation, who were diagnosed
with rheumatoid arthritis, osteoarthritis, spondylitis, or
any other chronic pain syndrome. Segmented regression
analysis was used to model the impact of policy on WVM
expenditures. In phase II, patients who were newly diag-
nosed with any of the above-mentioned disorders, and for
whom a request for PA was received, were identified and
classified into two groups. Group I consisted of patients
who were approved a branded NSAID. Group II consisted
of patients who were denied a branded NSAID and
switched to a generic product. HRQoL was measured at
the time the patient was identified and two months later
using the Arthritis Impact Measurement Scales (AIMS).
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New therapies are available to manage rheumatoid arthri-
tis (RA) patients who fail currently available DMARD
therapies. Data on patterns of DMARD use will be useful
in evaluating new therapies. 
OBJECTIVE: Identify patterns of initial DMARD ther-
apy in RA patients. 
METHODS: We used claims data from an MCO to iden-
tify RA patients who 1) were 18 years of age, 2) were
prescribed a DMARD for 2 consecutive months between
July 1993 and February 1998, 3) had a diagnosis of RA
during 6 months prior to DMARD therapy, and 4) had 6
months of enrollment before initial DMARD therapy.
Among patients using alternative therapies, we compared
patient characteristics, duration of therapy and changes
in initial therapy. 
RESULTS: 564 patients met the inclusion criteria. Mean
age was 51 years; 60% were female; and 78% received
their initial prescription from a rheumatologist. Median
duration of initial therapy was 16 months for methotrex-
ate (n  196), 11 months for hydroxychloroquine (n 
260), 5 months for sulfasalazine (n  51), and 5 months
for other therapies (n  57). For the two most commonly
used DMARDS, hydroxychloroquine patients were sig-
nificantly more likely (adjusted odds ratio 1.44, p 
0.004) than methotrexate patients to discontinue all
DMARD therapy, switch to an alternative DMARD, or
begin taking one or more additional DMARDS.
CONCLUSIONS: Many RA patients change initial
DMARD therapy within 1 year, suggesting a potential
role for new therapies directed toward patients who fail
currently available first-line drugs.
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The Health Assessment Questionnaire Disability Index
(HAQ) has been proven to be a valid and reliable mea-
sure of daily living ability of arthritis patients. 
OBJECTIVE: To establish the clinically meaningful im-
provements of the HAQ and its domain scores among
RA patients. 
METHODS: Data were obtained from two 12-week ran-
domized clinical trials among 2252 RA flare patients.
The HAQ, Patient and Physician Global Assessments
(PtGA & PhGA) were administered to patients at base-
line and week 12. HAQ is a 20-item instrument that con-
tains eight categories of daily living activities. A compos-
ite score is calculated. PtGA & PhGA were measured on
the following 1- to 5-point scale: very good, good, fair,
poor, or very poor. Change scores were computed by
subtracting patients’ baseline from week 12 follow-up
scores. Responsiveness was estimated as the mean change
score corresponding to each level of improvement in
PtGA or PhGA.
RESULTS AND CONCLUSIONS: At week 12, the num-
ber of patients experiencing improvements in PtGA and
PhGA were: 783 and 796 for one-level, 387 and 388 for
two-levels, and 87 and 85 for three or more levels. The av-
erage improvement in HAQ disability index among pa-
tients experiencing one, two, or three or more levels were
0.25, 0.47, 0.76 for PtGA and 0.26, 0.46, and 0.64 for
PhGA. Using the change score corresponding to a one-level
improvement or using the average difference of change be-
tween any two levels of improvement of PtGA or PhGA, the
clinically meaningful improvement score ranged from 0.21
to 0.26. Using similar methods, the clinically meaningful
improvement scores for the following eight categories of
daily living were: dressing (0.29), eating (0.22), arising
(0.35), walking (0.24), hygiene (0.15), reach (0.21), grip
(0.24), and activities (0.28), respectively.
